Kalnik Matthew W. 4
4 · NABI BIOPHARMACEUTICALS · Filed Mar 4, 2010
Insider Transaction Report
Form 4
Kalnik Matthew W.
SVP Strategic Plan. & Bus. Ops
Transactions
- Other
Common Stock
2009-11-30$2.41/sh+5,404.282$13,000→ 39,523.104 total - Exercise/Conversion
Common Stock
2010-03-02$3.95/sh+2,250$8,888→ 41,773.104 total - Exercise/Conversion
Stock Option (Right to Buy)
2010-03-02−2,250→ 15,750 totalExercise: $3.95Exp: 2015-04-01→ Common Stock (2,250 underlying) - Sale
Common Stock
2010-03-02$5.45/sh−2,250$12,263→ 39,523.104 total
Footnotes (3)
- [F1]Voluntarily reported acquisition under the Issuer's Employee Stock Purchase Plan, which is an exempt transaction pursuant to Rule 16b-3.
- [F2]The acquisition and sale of 2,250 shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F3]One-quarter of this Option became exercisable on April 1, 2009. The remaining three-quarters of the Option will become exercisable in three equal installments on April 1, 2010, April 1, 2011 and April 1, 2012.